Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

DSpace Repository

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author: Petrylak, Daniel P.; de Wit, Ronald; Chi, Kim N.; Drakaki, Alexandra; Sternberg, Cora N.; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed A.; Flechon, Aude; Bamias, Aristotelis; Yu, Evan Y.; van der Heijden, Michiel S.; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Geczi, Lajos; Ou, Yen-Chuan; Coskun, Hasan Senol; Su, Wen-Pin; Bedke, Jens; Gakis, Georgios; Percent, Ivor J.; Lee, Jae-Lyun; Tucci, Marcello; Semenov, Andrey; Laestadius, Fredrik; Peer, Avivit; Tortora, Giampaolo; Safina, Sufia; Garcia del Muro, Xavier; Rodriguez-Vida, Alejo; Cicin, Irfan; Harputluoglu, Hakan; Tagawa, Scott T.; Vaishampayan, Ulka; Aragon-Ching, Jeanny B.; Hamid, Oday; Liepa, Astra M.; Wijayawardana, Sameera; Russo, Francesca; Walgren, Richard A.; Zimmermann, Annamaria H.; Hozak, Rebecca R.; Bell-McGuinn, Katherine M.; Powles, Thomas
Tübinger Autor(en):
Bedke, Jens
Gakis, Georgios
Published in: Lancet Oncology (2020), Bd. 21, H. 1, S. 105-120
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(19)30668-0
ISSN: 1474-5488
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)